Axsome Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Good morning and welcome back to the William Blair Biotech Focus Conference for 2021. It's the second day after a jampacked full immuno-oncology day yesterday. My name is Myles Minter. I'm the Senior Biotech Analyst here at the firm covering neurosciences and RNA-targeted therapeutics. And it's my absolute pleasure to welcome Herriot Tabuteau, who is on the line with me today, CEO of Axsome Therapeutics, to discuss this fireside chat.
Before we get started, I do need to point you to disclosures that are available on WilliamBlair.com. And secondly, at the bottom of your screen, you can see a function to submit Q&A. I will do the best I can to get through those, but please submit them as you'd like throughout the chat.
So with that, Herriot, thanks for joining us again. Always great to chat. Just get the formalities out of the way maybe just for the benefit of our listeners, you can provide a brief overview of the Company and where it stands today.
Sure
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
